Drug Trial Radar · NCT01024972
Safety Study of Dantrolene in Subarachnoid Hemorrhage
Last checked: Nov 19, 2026Latest source record: Mar 5, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Oct 2009
Primary completion
Jul 2013
Study completion Oct 2013
Sponsor
- Lead sponsor
- University of Massachusetts, WorcesterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- American Heart Association
- First posted
- Dec 3, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Subarachnoid hemorrhage (SAH) is a devastating acute brain injury due to bleeding onto the brain surface from a ruptured aneurysm. Cerebral vasospasm (cVSP; critical narrowing of brain arteries) is a known complication after SAH and significantly increases disability and death after SAH. Vasospasm is difficult to treat and can lead to stroke. Animal studies have shown that the muscles in the artery wall play a role in cVSP. Dantrolene has been FDA approved and extensively used in clinical practice as a muscle relaxant for more than 30 years. It has been shown to provide some benefit in animal studies of cVSP, as well as in a small number of humans. However, the first human studies have only been observational and over a short period of time. This study will evaluate the safety and tolerability of intravenous dantrolene given every 6 hours over seven days to patients with or at risk for cVSP after SAH. The goal is to determine if future efficacy studies should be done to determine if treatment with Dantrolene may improve the outcome of patients with cVSP after SAH.
Conditions
- Subarachnoid Hemorrhage
- Cerebral Vasospasm
Interventions
DantroleneDrug
Dantrolene 1.25mg/kg IV (includes 5% mannitol) every 6 hours x 7 days
PlaceboDrug
equiosmolar volume (5% mannitol) every 6 hours x 7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- HyponatremiaTime frame: Seven days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UMASS Medical School / UMass Memorial Medical Center
Worcester, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.